Attached files
file | filename |
---|---|
EX-32.2 - EXHIBIT 32.2 - Anthera Pharmaceuticals Inc | ex32_2.htm |
EX-32.1 - EXHIBIT 32.1 - Anthera Pharmaceuticals Inc | ex32_1.htm |
EX-31.2 - EXHIBIT 31.2 - Anthera Pharmaceuticals Inc | ex31_2.htm |
EX-31.1 - EXHIBIT 31.1 - Anthera Pharmaceuticals Inc | ex31_1.htm |
EX-10.41 - EXHIBIT 10.41 - Anthera Pharmaceuticals Inc | ex10_41.htm |
EX-10.39 - EXHIBIT 10.39 - Anthera Pharmaceuticals Inc | ex10_39.htm |
EX-10.38 - EXHIBIT 10.38 - Anthera Pharmaceuticals Inc | ex10_38.htm |
EX-10.37 - EXHIBIT 10.37 - Anthera Pharmaceuticals Inc | ex10_37.htm |
EX-10.36 - EXHIBIT 10.36 - Anthera Pharmaceuticals Inc | ex10_36.htm |
EX-10.35 - EXHIBIT 10.35 - Anthera Pharmaceuticals Inc | ex10_35.htm |
10-K - Anthera Pharmaceuticals Inc | a22118010k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Anthera Pharmaceuticals, Inc.
Hayward, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S--3 (No. 333-175095, No. 333-179043, No. 333-187771, No. 333-187780 and No. 333-210166) and Form S--8 (No. 333-165714, No. 333-168970, 333-172100, No. 333-180144, No. 333-186679 No. 333-196740 and No. 333-213956) of Anthera Pharmaceuticals, Inc. of our reports dated March 5, 2018, relating to the consolidated financial statements. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
San Francisco, California
March 5, 2018